STOCK TITAN

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine with a focus on non-animal-derived rhCollagen technology, has announced it will release its first quarter 2025 financial results on Wednesday, May 28, 2025, before U.S. markets open. The company develops innovative technologies and products for tissue regeneration and medical aesthetics applications.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+5.48% News Effect

On the day this news was published, CLGN gained 5.48%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets.

Collplant Logo

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com

Contacts:
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com

Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com 

Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-first-quarter-financial-results-302455030.html

SOURCE CollPlant

FAQ

When will CollPlant Biotechnologies (CLGN) report Q1 2025 earnings?

CollPlant Biotechnologies will report its Q1 2025 financial results on Wednesday, May 28, 2025, before the U.S. financial markets open.

What is CollPlant Biotechnologies' (CLGN) main business focus?

CollPlant Biotechnologies focuses on regenerative and aesthetics medicine, developing innovative technologies and products based on non-animal-derived rhCollagen for tissue regeneration and medical aesthetics.

What stock exchange is CollPlant Biotechnologies (CLGN) listed on?

CollPlant Biotechnologies is listed on the NASDAQ stock exchange under the ticker symbol CLGN.

What type of collagen technology does CollPlant (CLGN) use?

CollPlant uses non-animal-derived rhCollagen technology for its products and innovations.
Collplant Biotechnologies Ltd

NASDAQ:CLGN

CLGN Rankings

CLGN Latest News

CLGN Latest SEC Filings

CLGN Stock Data

17.89M
8.97M
10.16%
12.23%
0.33%
Biotechnology
Healthcare
Link
Israel
Rehovot